March 16, 2012 Ipsen Biopharm Ltd. Attention: Company SecretaryTermination of Distribution Rights • May 8th, 2012 • Medicis Pharmaceutical Corp • Pharmaceutical preparations
AMENDED AND RESTATED COLLABORATION AGREEMENT by and between UCYCLYD PHARMA, INC. and HYPERION THERAPEUTICS, INC. Dated March 22, 2012Collaboration Agreement • May 8th, 2012 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED COLLABORATION AGREEMENT is entered into this 22nd day of March 2012 (the “Effective Date”), by and between UCYCLYD PHARMA, INC., a Maryland corporation, with its principal place of business at 7720 N. Dobson Road, Scottsdale, Arizona, 85256 (hereinafter referred to as “Ucyclyd”) and HYPERION THERAPEUTICS, INC., a Delaware corporation, with its principal place of business at 601 Gateway Blvd., Suite 200, South San Francisco, CA 94080 (hereinafter referred to as “Hyperion”). Ucyclyd and Hyperion are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • May 8th, 2012 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 1 TO LICENSE AND SETTLEMENT AGREEMENT (this “Amendment”) dated as of February 29, 2012 (the “Amendment Date”), is entered into between Medicis Pharmaceutical Corporation, a Delaware corporation with an address at 7720 North Dobson Road, Scottsdale, Arizona 85256 on behalf of itself and its Affiliates (collectively, “Medicis”), and Ranbaxy Inc., a Delaware corporation with an address at 600 College Road East, Princeton, New Jersey 08540 and Ranbaxy Laboratories Limited, a corporation organized under the laws of the Republic of India with an address at Plot 90, Sector 32, Gurgaon (Haryana) India - 122001, on behalf of themselves and their respective Affiliates (collectively, “Ranbaxy”).
